Taxus Cardium’s Excellagen Chosen as Stem Cell Matrix in Wound Trial – Drug Discovery & Development
| Drug Discovery & Development Taxus Cardium Pharmaceuticals Group Inc. announced that the company’s Excellagen flowable dermal matrix in combination with Orbsen Therapeutics’ mesenchymal stromal stem cell therapy Cyndacel-M has been selected for clinical evaluation in a Phase … |
